NEW YORK / Feb 27, 2023 / Business Wire / DocGo Inc (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that Anthony Capone, Chief Executive Officer will present at the upcoming Cowen 43rd Annual in Boston on Tuesday, March 7 at 2:10PM Eastern Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.
Also, Mr. Capone will present virtually at the upcoming Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 9:20AM Eastern Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.
About DocGo
DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with Ambulnz by DocGo's integrated medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
Last Trade: | US$1.31 |
Daily Change: | 0.04 3.46 |
Daily Volume: | 224,941 |
Market Cap: | US$128.520M |
August 07, 2025 August 06, 2025 May 08, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load